Dutasteride delays progression of prostate cancer in REDEEM trial

The abstract for the presentation of the resulsts of the REDEEM trial (to be presented on Thursday at the Gentourinary Cancer Symposium in Orlando) was published this evening on the ASCO web site. The data show that dutasteride delayed progression of prostate cancer in a well-defined group of patients compared to placebo therapy. … READ MORE …

Prostate cancer news updates: Sunday, June 7, 2009

Today’s news reports deal with:

  • Diabetes, PSA, and prostate cancer risk
  • Magnetic resonance spectroscopic imaging
  • Ongoing trials of dutasteride as early stage treatment for prostate cancer … READ MORE …